Evidence map›Paper›PMID 24036273›Full record

ReviewAdvanced drug delivery reviews2013

Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities.

Ameya R Kirtane, Stephen M Kalscheuer, Jayanth Panyam

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
11.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

79 citing papers in PubMed, 1 synthesis or guideline pooled it, 248 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Cellular and molecular aspects of drug resistance in cancers.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Review
  19. Article
  20. Article

19 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Ameya R KirtaneDepartment of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, USA.
Stephen M Kalscheuer
Jayanth Panyam
University of Minnesota · US

Funding

DUAL-AGENT NANOPARTICLES TO OVERCOME DRUG RESISTANCER21CA116641 · NCI · UNIVERSITY OF MINNESOTA · PI PANYAM, JAYANTH · 2007 to 2008
$299k
Sustained Release Curcumin Microspheres for Breast Cancer ChemopreventionR03CA141996 · NCI · UNIVERSITY OF MINNESOTA · PI PANYAM, JAYANTH · 2009 to 2010
$151k
NCI NIH HHS CA093453NCI NIH HHS CA116641NCI NIH HHS R03 CA141996NCI NIH HHS R21 CA116641
6 · The paper itself

Abstract

Tumor cells develop resistance to chemotherapeutic drugs through multiple mechanisms. Overexpression of efflux transporters is an important source of drug resistance. Efflux transporters such as P-glycoprotein reduce intracellular drug accumulation and compromise drug efficacy. Various nanoparticle-based approaches have been investigated to overcome efflux-mediated resistance. These include the use of formulation excipients that inhibit transporter activity and co-delivery of the anticancer drug with a specific inhibitor of transporter function or expression. However, the effectiveness of nanoparticles can be diminished by poor transport in the tumor tissue. Hence, adjunct therapies that improve the intratumoral distribution of nanoparticles may be vital to the successful application of nanotechnology to overcome tumor drug resistance. This review discusses the mechanisms of tumor drug resistance and highlights the opportunities and challenges in the use of nanoparticles to improve the efficacy of anticancer drugs against resistant tumors.

Indexed as

Drug Resistance, NeoplasmNanotechnologyAnimalsAntineoplastic AgentsBiological TransportDrug CarriersDrug DesignHumansNanoparticlesNeoplasmsNeovascularization, PathologicAntineoplastic AgentsDrug CarriersABCATP-binding cassetteBCRPbreast cancer resistance proteincancer stem cellsCMCcritical micellar concentrationCSCsECMEfflux inhibitorsEfflux transportersEGFEGFREMTEndocytosisepidermal growth factorepidermal growth factor receptorepithelial to mesenchymal transitionExcipientsextracellular matrixExtracellular matrixGFPgreen fluorescent proteinHIFhistidine rich glycoproteinHLBHREHRGhydrophilic lipophilic balancehypoxia inducible factorhypoxia responsive elementIFPinterstitial fluid pressureInterstitial fluid pressureMDRMRPmultidrug resistancemultidrug resistance associated proteinNanoparticlesNBDsNPsnucleotide binding domainsPEGP-glycoproteinP-gpphosphoinositol-3-kinasePI3KPLGApoly(ethylene glycol)poly(lactide-co-glycolide)TGF βTMDstransforming growth factor βtransmembrane domainsTransport barriersTumor penetrationvascular endothelial growth factorvascular endothelial growth factor receptorVEGFVEGFR

Identifiers

PMID24036273
PMCPMC3849460
OpenAlexW2050564805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.